Dianthus Therapeutics DNTH Business Segments
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Discovery Expenses | $1.36M+2,030% | $64K-61.9% | $168K-81.3% | $900K+118% | $412K-39.9% | |
| Other Costs | $1.49M+20.7% | $1.24M+2.5% | $1.21M+1.4% | $1.19M— | —— | |
| Personnel And Related Costs | $8.64M+225% | $2.66M-55.4% | $5.96M+2.0% | $5.85M-45.0% | $10.64M+395% | |
| Share Based Compensation Expense | $4.85M+48.7% | $3.26M+32.6% | $2.46M-0.6% | $2.48M— | —— | |
| General And Administrative Expense by Product | ||||||
| Other Costs | $2.65M+16.7% | $2.27M-19.6% | $2.83M+46.1% | $1.94M-18.1% | $2.36M+6.1% | |
| Personnel And Related Costs | $4.06M-36.5% | $6.4M+129% | $2.79M+9.1% | $2.56M— | $0-100% | |
| Share Based Compensation Expense | $5.75M+127% | $2.53M-22.0% | $3.25M+14.3% | $2.84M— | —— | |
| Claseprubart Program Related Expenses by Product | ||||||
| Clinical Operation Activities | $14.16M— | —— | —— | $11.74M— | —— | |
| CMC Activities | $3.71M— | —— | —— | $3.81M— | —— | |
| Preclinical Study Activity Costs | $320K— | —— | —— | $1.04M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Dianthus Therapeutics break its business down?
- Dianthus Therapeutics (DNTH) reports research and development expense by product across 4 parts — Discovery Expenses, Other Costs, Personnel And Related Costs and Share Based Compensation Expense. Each is extracted from the segment footnotes and tracked over time.
- Where does Dianthus Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Dianthus Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.